4BB 4basebio Plc

 
TIDM4BB 
 
23 November 2021 
 
                                 4basebio PLC 
 
                  ("4basebio", the "Company" or the "Group") 
 
                  Joint Development Agreement with Leucid Bio 
                    for novel CAR T-cell production methods 
 
4basebio PLC (AIM: 4BB), the specialist life sciences group focused on 
exploiting intellectual property in the field of cell and gene therapies and 
DNA vaccines, is pleased to announce a Joint Development Agreement ("JDA") 
between its wholly owned subsidiary 4basebio Discovery Limited and Leucid Bio 
Limited, a biotech company pioneering next-generation Chimeric Antigen Receptor 
T-Cell ("CAR-T") Therapies  for hard-to-treat cancers. 
 
CAR-T therapy is an ex-vivo cell therapy which involves genetically 
reprogramming a patient's T-cells to recognise and destroy cancer cells. While 
current practice relies on integrating viral vectors to deliver the genetic 
payloads to generate the CAR T-cells, non-viral based approaches, such as 
MaxCyte's electroporation technology, are gaining popularity given their 
scalability, improved safety profile and flexibility in delivering payloads 
aimed at creating allogeneic, off-the-shelf CAR T-cells. 
 
Under the JDA, the companies will evaluate the use of 4basebio's HermesT 
non-viral nanoparticle and synthetic hpDNATM technology for enhanced delivery 
of genetic payloads to generate CART-cells. The successful outcome of this 
project will pave the way for development of a novel, high-performance and more 
cost-effective cell engineering method for CAR-T products. 
 
Leucid Bio recently closed a £11.5m Series A financing round to progress its 
ongoing development of next generation CAR-T therapies. The company's pCAR 
technology gives properties to the cells that enable them to consistently 
outperform previous generations of CAR-T therapies in pre-clinical studies. 
 
Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: "We are very excited to be 
working with Leucid Bio, a pioneer in next-generation CAR-T therapies, in 
developing a novel cell engineering approach for CAR-T products." 
 
Artin Moussavi, CEO of Leucid Bio, said: "We are delighted to be working with 
4basebio in developing a safer, more scalable cell engineering process for the 
generation of allogeneic CAR-T therapies using their innovative HermesTM 
non-viral delivery platform." 
 
 
For further enquiries, please contact: 
 
4basebio PLC                                                     +44 (0)12 2396 
7943 
Heikki Lanckriet 
 
Nominated Adviser                                            +44 (0)20 7213 
0880 
Cairn Financial Advisers LLP 
Jo Tuner / Sandy Jamieson 
 
Broker                                                                +44 (0)20 
7220 0500 
finnCap Ltd 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe 
 
 
Notes to Editors 
 
About 4basebio 
 
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic 
DNA for cell and gene therapies and DNA vaccines and providing solutions for 
effective and safe delivery of these DNA based products to patients. It is the 
intention of the Company to become a market leader in the manufacture and 
supply of high purity, synthetic DNA for research, therapeutic and 
pharmacological use and develop non-viral vectors for the efficient delivery of 
payloads. The immediate objectives of 4bb are to validate and scale its DNA 
synthesis and advance its collaborations to facilitate the functional 
validation of its DNA based products and cell and gene delivery solutions. 
 
About Leucid Bio 
 
Leucid Bio is a pioneering biotech company developing cell therapies for 
refractory cancers, especially solid tumours. Leucid was founded to translate 
20 years of King's College London (King's) research in the CAR-T field and is 
led by a highly experienced management team with both scientific and commercial 
expertise. As part of Leucid's ongoing relationship with King's, it benefits 
from exclusive access to and resources from the deep scientific, clinical and 
manufacturing expertise of Dr Maher and his academic team of immuno-oncology 
experts. 
 
Leucid is headquartered in London, UK, with operations based at Guy's Hospital 
with its own GMP manufacturing and clinical lab facilities, enabling it to 
maintain its patient-centric focus on developing better cell therapies for the 
benefit of individuals with hard-to-treat solid tumours. 
 
Forward-looking statements 
 
This announcement may contain certain statements about the future outlook for 
the 4basebio.  Although the directors believe their expectations are based on 
reasonable assumptions, any statements about future outlook may be influenced 
by factors that could cause actual outcomes and results to be materially 
different. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

November 23, 2021 02:00 ET (07:00 GMT)

4basebio (LSE:4BB)
Historical Stock Chart
From Mar 2024 to Apr 2024

4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2023 to Apr 2024